This is a summary. To read the whole story subscribe to BostonGlobe.com
Charles River Laboratories ticked higher on a $179 million deal to buy a pair of European drug-targeting businesses that will help it expand as a contract researcher for pharma and biotech companies. The acquisition of Argenta and BioFocus, two British units of Dutch drug maker Galapagos NV, will allow Charles River to offer clients early-stage “in vitro” tests for drug targets, using cellular systems and computer simulations. “It gives us a broader, much more comprehensive portfolio than any other contract research organization in the world,” said CEO James C. Foster. The deal is expected to be completed this spring.